KALA BIO, Inc.
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more
Market Cap & Net Worth: KALA BIO, Inc. (0JQ2)
KALA BIO, Inc. (LSE:0JQ2) has a market capitalization of $2.36K ($2.36K) as of March 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #34319 globally and #495 in its home market, demonstrating a -7.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying KALA BIO, Inc.'s stock price $0.24 by its total outstanding shares 9843 (9.84K).
KALA BIO, Inc. Market Cap History: 2026 to 2026
KALA BIO, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $2.36K to $2.36K (0.00% CAGR).
KALA BIO, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how KALA BIO, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0JQ2 by Market Capitalization
Companies near KALA BIO, Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to KALA BIO, Inc. by market ranking:
- Nevada Exploration Inc (OTCQB:NVDEF): Ranked #34310 globally with a market cap of $1.97 Million USD.
- My Size Inc (NASDAQ:MYSZ): Ranked #34311 globally with a market cap of $1.97 Million USD.
- Monumental Minerals Corp (OTCQB:MNMRF): Ranked #34320 globally with a market cap of $1.97 Million USD.
- REPUBLIC SERVICES - Dusseldorf Stock Exchang (DU:RPU): Ranked #34321 globally with a market cap of $1.96 Million USD ( €1.91 Million EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #34310 | Nevada Exploration Inc | OTCQB:NVDEF | $1.97 Million | $0.09 |
| #34311 | My Size Inc | NASDAQ:MYSZ | $1.97 Million | $0.63 |
| #34320 | Monumental Minerals Corp | OTCQB:MNMRF | $1.97 Million | $0.04 |
| #34321 | REPUBLIC SERVICES - Dusseldorf Stock Exchang | DU:RPU | $1.96 Million | €191.45 |
KALA BIO, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, KALA BIO, Inc.'s market cap moved from $2.36K to $ 2.36K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.36K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of KALA BIO, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.36K USD |
| MoneyControl | $2.36K USD |
| MarketWatch | $2.36K USD |
| marketcap.company | $2.36K USD |
| Reuters | $2.36K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.